Alurol is used to decrease uric acid concentrations in plasma and/or urine when hyperuricaemia is clinically significant. Alurol and its active metabolite oxypurinol inhibit xanthine oxidase, the enzyme responsible for the conversion of hypoxanthine to xanthine to uric acid. Inhibition of this enzyme accounts for the major pharmacological effects of Alurol. In contrast with the uricosuric agents that increase the renal excretion of urate, Alurol inhibits the terminal steps in uric acid biosynthesis.
90% of the Alurol from tablets is absorbed in the gastro-intestinal tract. The Alurol is rapidly metabolized to the active metabolite oxypurinol (alloxanthine). After administration, peak plasma levels occur generally at 1.5 hrs for Alurol. It has a plasma half-life of approximately 1 hour.